Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02018133 · ClinicalTrials.gov registry record
Identification of Markers for Determining the Efficacy of Vitamin D Receptor Activator Therapy in Stage 3/4 CKD Patients
A clinical trial of CKD Stage 3/4, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- 8
- Enrollment target
- 1
- Study location
NCT02018133: Completed study of CKD Stage 3/4, sponsored by University of Illinois at Chicago.
NCT02018133 is a study of CKD Stage 3/4 that has completed, run by University of Illinois at Chicago. The registered enrollment target is 8 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02018133, a study of CKD Stage 3/4, has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to identify genes that are responsive to paricalcitol (active vitamin D) therapy. Scientists have found that over 30 different types of cells in the body respond to vitamin D therapy, including blood vessels. Low levels of vitamin D may reduce the amount of calcium in the blood, increase the amount of parathyroid hormone (PTH) and cause the parathyroid gland (small gland located in the neck) to get bigger which is called secondary hyperparathyroidism (SHPT). Also, low levels of vitamin D may worsen the heart disease seen in dialysis patients. Paricalcitol, a man-made active vitamin D, is a replacement for vitamin D for preventing and treating SHPT. Studies that followed patients on dialysis have found: (1) differences in death rates between those who received active vitamin D compared with no activated vitamin D, and (2) a survival benefit in chronic kidney disease (CKD) patients receiving paricalcitol, over calcitriol (natural active vitamin D). Researchers have considered that giving paricalcitol to people with (CKD) may also prevent or slow the progression of heart disease. Currently, physicians can only tell how well the vitamin D is working by measuring PTH concentrations. This study aims to identify markers in the blood that can be used to determine the efficacy of Vitamin D therapy.
Primary Outcome
determine gene expression
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Vitamin D 2mg daily for 2 weeks oral paricalcitol
Study Locations (1)
Illinois
- University of Illinois at Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2009-12 |
| Est. Completion | 2012-06 |
What the finished NCT02018133 record still lists
NCT02018133 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 8 participants, a relatively small participant target.
The record links to 1 condition, with CKD Stage 3/4 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02018133 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT02018133 about?
NCT02018133 is a clinical study titled "Identification of Markers for Determining the Efficacy of Vitamin D Receptor Activator Therapy in Stage 3/4 CKD Patients". The purpose of this study is to identify genes that are responsive to paricalcitol (active vitamin D) therapy. Scientists have found that over 30 different types of cells in the body respond to vitamin D therapy, including blood vessels. Low levels of vitamin D may reduce the amount of calcium in th...
What is the current status of trial NCT02018133?
This trial is currently completed. The enrollment target is 8 participants. The study started on 2009-12. Estimated completion is 2012-06.
What conditions does trial NCT02018133 study?
This clinical trial studies the following conditions: CKD Stage 3/4.
What interventions are being tested in trial NCT02018133?
The interventions under investigation include: Placebo (DRUG), Vitamin D 2mg daily for 2 weeks oral paricalcitol (DRUG).
Who is sponsoring clinical trial NCT02018133?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02018133 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia